Table of Contents

• Overview of Venetoclax trials
• Conditions being studied
• Trial designs and phases
• Main endpoints being measured
• Who may be able to participate
• Important trial examples
• Patient-friendly explanation of key terms

Overview of Venetoclax trials

These clinical trials study Venetoclax in many cancer settings and in a few other diseases.^[1] Most studies test Venetoclax as part of a combination, not as a single treatment.^[2] The main goals are to learn about safety, tolerability, and how well the treatment works in specific patient groups.^[3]

The trial data show a wide range of study sizes, from small early studies to large Phase 3 trials with hundreds of patients.^[4] Some studies are completed, while others are authorised or suspended.^[5]

Conditions being studied

Many trials focus on acute myeloid leukemia (AML), including newly diagnosed AML, relapsed or refractory AML, and AML with specific genetic changes such as NPM1, KMT2A, FLT3, IDH1, or RARA-related disease.^[6] Several studies also include chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), including first-line, relapsed, and high-risk disease.^[7]

Other blood cancers in the trial set include mantle cell lymphoma, multiple myeloma, Waldenström’s macroglobulinemia, chronic myelomonocytic leukemia (CMML), and myelodysplastic syndrome (MDS).^[8] There are also studies in blastic plasmacytoid dendritic cell neoplasm, Richter syndrome, and acute graft-versus-host disease of the skin.^[9]

A few trials look beyond cancer, including studies in HIV-1 disease and HIV-1 infection, where the aim is to study safety and effects on the HIV reservoir, which means the hidden pool of virus in the body.^[10]

Trial designs and phases

The trials include Phase 1, Phase 2, Phase 3, and some Phase 4 studies.^[11] Phase 1 studies mainly check safety, dose limits, and the recommended dose for later testing.^[12] Phase 2 studies often look at early signs of benefit, such as remission or MRD negativity.^[13]

Phase 3 studies are larger and usually compare Venetoclax combinations with another treatment, placebo, or standard care.^[14] Some studies are open-label, which means both the researchers and participants know which treatment is being given.^[15] Other studies are randomized, meaning patients are assigned by chance to different treatment groups.^[16]

Main endpoints being measured

The most common endpoints are overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and response rates such as overall response rate (ORR) or complete remission (CR).^[17] These endpoints help show whether a treatment helps people live longer, stay well longer, or have a better cancer response.^[18]

Many trials also use minimal residual disease (MRD) or undetectable MRD (uMRD) as important endpoints.^[19] MRD testing looks for very small amounts of cancer that may remain after treatment, even when the patient seems to be in remission.^[20] Some studies also measure dose-limiting toxicities, adverse events, and pharmacokinetics, which is how the body handles a treatment.^[21]

Who may be able to participate

Eligibility depends on the trial and the disease being studied.^[22] Some studies are for people who have never been treated before, while others are for people whose cancer has returned or did not respond to earlier therapy.^[23]

Several studies focus on special groups, such as older adults, people who are not fit for intensive chemotherapy, patients with specific genetic changes, or patients who already reached remission but still have MRD.^[24] Some trials also look at people after stem cell transplantation or after previous Venetoclax treatment.^[25]

Important trial examples

NCT02993523 studied Venetoclax plus azacitidine versus azacitidine alone in previously untreated AML, with outcomes of CR/CRi and overall survival.^[26] NCT03069352 tested Venetoclax with low-dose cytarabine in untreated AML patients who were not eligible for intensive chemotherapy, with overall survival as the main endpoint.^[27]

NCT04608318, NCT06073821, and NCT05057494 are large Phase 3 studies in previously untreated CLL or CLL/SLL that compare Venetoclax-based regimens with other treatment approaches and measure PFS.^[28] NCT06943872 and NCT04965493 study relapsed or refractory CLL/SLL and compare Venetoclax-based retreatment or combinations against other options using PFS or response-based outcomes.^[29]

NCT02899052 and NCT03539744 focus on multiple myeloma, especially t(11;14)-positive disease, and measure response rates and PFS.^[30] NCT05099471 studies Venetoclax with rituximab in Waldenström’s macroglobulinemia and looks at complete or very good partial remission rates.^[31]

NCT04581512, NCT06156579, NCT04763928, and NCT05431257 are examples of AML and related myeloid disorder studies that test Venetoclax with other agents and measure remission, EFS, or response rates.^[32] NCT05807932 and NCT2025-521372-62-00 study Venetoclax around allogeneic stem cell transplantation and measure safety or survival after transplant.^[33]

Patient-friendly explanation of key terms

Combination therapy means Venetoclax is given with one or more other drugs in the same study.^[34] Maintenance therapy means treatment given after the main treatment phase to help keep the disease under control.^[35]

Relapsed means the disease came back after treatment, and refractory means it did not respond well to treatment.^[36] Randomized means patients are assigned by chance to different study groups, which helps compare treatments fairly.^[37]

Open-label means the treatment is known to everyone in the study.^[38] Blinded independent review or central review means outside experts check the results in a standard way, which helps reduce bias.^[39]

Table of Contents

• What is Trametinib?
• How Trametinib Works
• Conditions Treated with Trametinib
• How Trametinib is Administered
• Ongoing Clinical Trials
• Potential Side Effects

What is Trametinib?

Trametinib is a medication used in cancer treatment. It is known by several names, including:

• Mekinist (brand name)
• GSK1120212
• JTP-74057
• MEK Inhibitor GSK1120212

Trametinib belongs to a class of drugs called MEK inhibitors. These drugs work by blocking certain proteins involved in cancer cell growth.^[1]

How Trametinib Works

Trametinib targets and blocks proteins called MEK1 and MEK2. These proteins are part of a pathway in cells that controls growth and survival. In many types of cancer, this pathway is overactive, causing cancer cells to grow and spread uncontrollably. By inhibiting MEK1 and MEK2, trametinib can help stop or slow the growth of cancer cells.^[2]

Specifically, trametinib blocks an enzyme pathway that cancer cells need to grow. When these proteins are blocked, cancer cell growth may be stopped, and the cancer cells may die.^[1]

Conditions Treated with Trametinib

Trametinib is being studied and used to treat various types of cancer, including:

• Advanced or metastatic solid tumors: This refers to cancers that have spread from their original location to other parts of the body.^[3]
• Thyroid cancer: Particularly radioiodine-refractory thyroid cancer, which doesn’t respond to standard radioactive iodine treatment.^[4]
• Cervical cancer: Specifically for recurrent or persistent cervical cancer.^[5]
• Oral cavity squamous cell cancer: A type of mouth cancer.^[2]
• Multiple myeloma: A cancer of plasma cells in the bone marrow.^[6]
• Non-small cell lung cancer (NSCLC): Particularly in patients with certain genetic mutations.^[7]
• Langerhans Cell Histiocytosis (LCH): A rare disorder that can affect various parts of the body.^[8]

How Trametinib is Administered

Trametinib is typically taken orally (by mouth) once daily. The dosage may vary depending on the specific condition being treated and the patient’s individual factors. Some key points about trametinib administration include:

• It is usually given in 28-day cycles.^[6]
• The typical adult dose is 2 mg once daily.^[7]
• For patients who cannot swallow pills, a liquid formulation may be available.^[8]
• Dose adjustments may be necessary based on how well the patient tolerates the medication.^[7]

Ongoing Clinical Trials

Trametinib is being studied in various clinical trials to better understand its effectiveness and safety in different types of cancer. Some ongoing areas of research include:

• Combining trametinib with other medications to enhance its effectiveness.^[4]
• Using trametinib in patients with liver dysfunction.^[1]
• Studying trametinib’s effects on specific genetic mutations in cancer cells.^[7]
• Evaluating trametinib as a treatment for rare disorders like Langerhans Cell Histiocytosis.^[8]

Potential Side Effects

Like all medications, trametinib can cause side effects. Common side effects may include:

• Skin rashes or other skin problems
• Diarrhea
• Fatigue
• Nausea
• Swelling (edema)

More serious side effects can occur, such as heart problems, eye problems, or lung inflammation. Patients should report any unusual symptoms to their healthcare provider promptly.^[1]

It’s important to note that the side effects and their frequency can vary depending on the specific condition being treated and other factors. Your healthcare team will monitor you closely while you’re taking trametinib and can provide more personalized information about potential side effects.

Table of Contents

• Overview of the trials
• Trials in advanced liver cancer
• Trials in children and young adults
• Trials in other cancers
• Main endpoints studied
• Who may be able to join
• Study phases and what they mean

Overview of the trials

These studies look at Sorafenib as part of cancer treatment research, mainly in liver cancer and in some other cancer types.^[1] The trials test Sorafenib alone as a standard treatment comparator, or together with other drugs, to see which approach gives better results.^[1][2]

Most of the trials are interventional, which means researchers give a treatment and then measure the results.^[1] The studies include both large Phase 3 trials and smaller Phase 1 or Phase 2 trials.^[1][2]

Trials in advanced liver cancer

Several trials focus on hepatocellular carcinoma (HCC), which is the most common type of liver cancer.^[1][2][4][6] Some studies include people with advanced HCC who have not had prior systemic therapy, meaning they have not yet received treatment that works throughout the body.^[1][2][4]

In NCT04039607, the main question is whether nivolumab plus ipilimumab improves overall survival compared with standard care, which includes Sorafenib or lenvatinib.^[1] In NCT03298451, researchers compare durvalumab alone or with tremelimumab against Sorafenib in people with unresectable advanced HCC.^[2]

NCT04039607 has 763 participants and NCT03298451 has 1604 participants, so these are large studies designed to compare treatments in many people.^{[1][2] Another Phase 3 study, 2024-516479-34-00, compares cabozantinib plus atezolizumab with Sorafenib in advanced HCC and measures progression-free survival and overall survival.[4]}

Study 2022-502948-13-00 looks at locally advanced or metastatic HCC in Child-Pugh A patients, which means the liver is still working well enough to meet the study rules.^[6] This Phase 2 study tests whether livmoniplimab plus budigalimab can produce a confirmed complete or partial response before the next cancer treatment starts.^[6]

Trials in children and young adults

The Paediatric Hepatic International Tumour Trial, NCT03017326, includes children and young people with hepatoblastoma and HCC.^[5] Sorafenib appears in one treatment group for unresected HCC, where the study asks whether adding gemcitabine, oxaliplatin, and Sorafenib to cisplatin and doxorubicin improves outcomes.^[5]

This is a Phase 3 study with 449 participants and several risk groups, including very low-risk, low-risk, intermediate-risk, high-risk, resected HCC, and unresected HCC.^[5] The study also collects samples for biological and toxicity studies in some groups, which helps researchers learn more about the disease and treatment effects.^[5]

Trials in other cancers

Not all Sorafenib studies are in liver cancer. Trial 2024-512887-77-00 studies advanced-stage malignancies with BRAF mutations, which are changes in a gene that can affect how cancer grows.^[3] This Phase 1 study tests Sorafenib with trametinib to find the maximum tolerated dose and the recommended phase II dose.^[3]

Trial 2026-525223-24-00 studies pediatric and young adult patients with high-risk osteosarcoma, including relapsed or refractory disease.^[7] It compares mifamurtide with standard treatment containing Sorafenib and measures event-free survival, meaning the time until the first bad event such as death, progression, or relapse.^[7]

One completed Phase 2 trial, 2023-509092-16-00, included older patients with acute myeloid leukemia, myelodysplastic syndrome, and chronic myelomonocyte leukemia.^[5] In that study, Sorafenib was part of a precision therapy strategy, and the main outcome was cost-effectiveness measured through quality-adjusted life-years, or QALYs, which combine length of life and quality of life.^[5]

Main endpoints studied

The most common endpoint is overall survival, which means how long people live after randomization, no matter what causes death.^[1][2][4]

Other important endpoints include progression-free survival, which measures how long the cancer stays from getting worse, and event-free survival, which measures the time until a first major event such as progression, relapse, or death.^[4][5][7]

Some studies measure tumor response using RECIST 1.1, a standard system for checking whether a tumor shrinks, stays stable, or grows.^[6] Other studies look at response rates, maximum tolerated dose, recommended phase II dose, toxicity samples, or cost-effectiveness.^[3][5]

Who may be able to join

Eligibility changes from study to study, but the trials here mainly include people with advanced HCC who have not had prior systemic therapy, people with unresectable liver cancer, children and young adults with hepatoblastoma or HCC, and patients with relapsed or refractory osteosarcoma.^{[1][2][5][6][7]}

One study also includes older patients with AML, MDS, or CMML who are considered unfit for standard treatment.^[5] Another requires Child-Pugh A liver function, which means the liver is still functioning well enough for the study rules.^[6]

Study phases and what they mean

Phase 3 trials are the largest studies in this set and are usually designed to compare one treatment with another and confirm whether it works better or is safer.^[1][2][4][5]

Phase 2 trials are smaller and often focus on how well a treatment works, which dose may be best, or whether a treatment strategy is worth testing further.^[5][6][7]

Phase 1 trials are the earliest studies here and mainly look at safety and dose finding, such as the maximum tolerated dose and the dose recommended for later testing.^[3]

Table of Contents

• What is Letrozole?
• How Letrozole Works
• Conditions Treated with Letrozole
• Dosage and Administration
• Combination Therapies
• Side Effects and Safety
• Ongoing Research

What is Letrozole?

Letrozole is a medication primarily used in the treatment of breast cancer. It belongs to a class of drugs called aromatase inhibitors. Letrozole is also known by the brand name Femara^[1]. This medication is typically prescribed for postmenopausal women with a specific type of breast cancer known as hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer^[1].

How Letrozole Works

Letrozole works by reducing the amount of estrogen in the body. It does this by blocking an enzyme called aromatase, which is responsible for producing estrogen. By lowering estrogen levels, letrozole can slow down or stop the growth of certain types of breast cancer cells that rely on estrogen to grow^[2].

Conditions Treated with Letrozole

While letrozole is primarily used for breast cancer treatment, research is ongoing to explore its potential in treating other conditions. Here are the main conditions for which letrozole is used or being studied:

• Advanced Breast Cancer: Letrozole is approved for treating postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer^[1]. This type of breast cancer has receptors that are sensitive to hormones like estrogen, but does not have high levels of a protein called HER2 on the cancer cells.
• Endometrial Cancer: Some studies are investigating the use of letrozole in treating advanced or recurrent endometrial cancer. Endometrial cancer is a type of cancer that begins in the lining of the uterus^[3].
• Ovarian Cancer: Research is being conducted to evaluate the effectiveness of letrozole in treating heavily pretreated recurrent ovarian cancer^[4]. Ovarian cancer is a type of cancer that begins in the ovaries.

Dosage and Administration

Letrozole is typically taken orally in tablet form. The standard dosage for breast cancer treatment is 2.5 mg once daily^[1]. It’s usually taken continuously, meaning you take it every day without breaks. Your doctor will determine the appropriate dosage and duration of treatment based on your specific condition and response to the medication.

Combination Therapies

In some cases, letrozole may be used in combination with other medications to enhance its effectiveness. One such combination that has been studied is letrozole with palbociclib (also known as PD-0332991 or Ibrance)^[2]. Palbociclib is a drug that works by blocking certain proteins in cancer cells, potentially making letrozole more effective. This combination is being studied for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Side Effects and Safety

Like all medications, letrozole can cause side effects. Common side effects may include:

• Hot flashes
• Joint pain
• Fatigue
• Headache
• Nausea

More serious side effects can occur, but they are less common. These may include an increased risk of osteoporosis (bone thinning) and cardiovascular events. Your doctor will monitor you closely for any side effects and adjust your treatment if necessary^[2].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of letrozole in various settings:

• Combination therapy with new drugs: Studies are exploring the combination of letrozole with newer drugs like PF-07220060 for breast cancer treatment^[5].
• Expanded access studies: These studies aim to provide access to letrozole for patients who might benefit from it but don’t qualify for other clinical trials^[6].
• Use in other cancers: As mentioned earlier, research is ongoing to evaluate the effectiveness of letrozole in endometrial and ovarian cancers^[3][4].

It’s important to note that while these studies show promise, more research is needed to fully understand the potential benefits and risks of letrozole in these new applications.

Table of contents

• Clinical trial overview
• Conditions studied
• Trial phases and study designs
• Who can participate
• What the trials measure
• Examples of important trials
• What these studies mean for patients

Clinical trial overview

These studies investigate Hydroxycarbamide in several different patient groups, mainly people with blood cancers, myeloproliferative neoplasms, and sickle cell disease.^[1][2][3] The trials do not all ask the same question: some look at safety, some look at treatment effect, and some compare Hydroxycarbamide with other therapies.^[4][5]

Conditions studied

Hydroxycarbamide is being studied in sickle cell disease, including pediatric sickle cell disease and drepanocytosis, which is another word used for sickle cell disease in one study.^[2][6][7] It is also studied in polycythemia vera, a disease where the body makes too many blood cells, and in myelofibrosis, which is a bone marrow disease that can enlarge the spleen and cause symptoms.^[3][8][9]

Other trials include people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML), especially older or unfit patients who may not be able to receive standard chemotherapy.^[4][10] One study also includes recurrent meningioma, which is a brain tumor that has come back and has no local treatment options left.^[11]

Another large study focuses on cancer care in Norway and uses Hydroxycarbamide among many commercially available targeted cancer drugs for patients with advanced malignancy and a matching molecular or protein marker.^[12]

Trial phases and study designs

The trials cover Phase 1, Phase 2, Phase 3, and Phase 4 research.^[2][3][4][8] Phase 1 studies mainly test safety and dose selection, while Phase 2 and Phase 3 studies focus more on response, comparison with other treatments, and longer-term outcomes.^[4][5][8] Phase 4 research in this set looks at treatment outcomes after earlier development stages, especially in myelofibrosis after JAK inhibitor treatment.^[9]

Some studies are open-label, which means everyone knows which treatment is being given, while others are randomized, which means patients are assigned to one treatment group or another by chance.^[2][5][11] Several trials compare Hydroxycarbamide with another active treatment or with best available therapy, and some studies use it as part of a combination regimen.^[3][4][5]

Who can participate

The target groups are different depending on the trial.^[2][4] Some studies include children aged 9 months to 11 years with sickle cell disease, while others include adults aged 18 years or older with newly diagnosed AML.^[2][4]

Several trials focus on patients with high-risk blood disorders such as polycythemia vera and myelofibrosis, including people who have already received ruxolitinib or other prior treatment.^[3][5][8] One study includes patients who are considered unfit for standard chemotherapy, which means they may not be able to tolerate the usual stronger treatment plan.^[10]

In the precision medicine cancer study, patients have advanced malignancy and a genomic or protein expression variant that may predict sensitivity to a drug, meaning the study looks for a biological marker that matches a treatment target.^[12]

What the trials measure

The main outcomes vary by study, but they usually measure how well the treatment works and how safe it is.^[2][3][4] In the pediatric sickle cell study, researchers measure pharmacokinetics, including area under the curve (AUC), time to maximum concentration (Tmax), and maximum plasma concentration (Cmax), to understand how the treatment behaves in the body over time.^[2]

In AML, one key endpoint is MRD-negativity after cycle 2, which means no measurable remaining leukemia cells are found with the test used in the study.^[4] In polycythemia vera and myelofibrosis trials, important outcomes include event-free survival, spleen volume reduction, and response at Week 48 or Week 24.^[3][5][8]

Safety outcomes include treatment-related grade 3 or higher adverse events, serious adverse events, tolerability, and the number and severity of side effects or toxicities.^[1][4][10] Some studies also measure quality of life, symptom scores, blood counts, or the time to reach a treatment goal such as low disease activity or response.^[5][6][9]

Examples of important trials

The KID-BID study is a Phase 2 trial in young children with sickle cell disease. It studies twice-daily Hydroxycarbamide dispersible tablets and measures drug exposure at 1, 3, 6, 9, and 12 months after treatment starts.^[2]

The HEAT-AML study is a Phase 1 trial in adults with newly diagnosed AML. It looks at adding Hydroxycarbamide to standard AML treatment and measures safety, tolerability, and MRD-negativity after the second chemotherapy cycle.^[4]

The polycythemia vera studies are larger Phase 3 trials. One compares Hydroxycarbamide with ruxolitinib or interferon alpha as first-line therapy, and another evaluates Hydroxycarbamide resistance or intolerance in patients with risk factors identified by an artificial intelligence project.^[5][8]

The myelofibrosis studies measure spleen volume response and event-free survival in patients with primary myelofibrosis or post-polycythemia vera/post-essential thrombocythemia myelofibrosis, often after prior treatment with a JAK inhibitor.^[3][9]

The essential thrombocythemia trial compares bomedemstat with Hydroxycarbamide and uses durable clinicohematologic response as the main endpoint, which means a lasting improvement in both clinical signs and blood test results.^[7]

What these studies mean for patients

These trials show that Hydroxycarbamide is being studied in many different ways, not only as a treatment by itself but also as a comparator, part of a combination, or a standard therapy used against newer drugs.^[1][3][5] The research includes both children and adults, and it covers early safety studies as well as larger studies that look at long-term response and disease control.^[2][4][8]

For patients, the most important idea is that each trial has its own entry rules and its own main goal, so the study population and the measured results can be very different from one trial to another.^{[2][5][10][12]}

Table of contents

• Trial overview
• Who is being studied
• How the trials are designed
• Main endpoints
• What the trials try to show
• Key patient terms

Trial overview

Two authorised Phase 3 clinical trials are studying Hexaminolevulinate in bladder cancer surgery.^[1][2] Both trials focus on non-muscle invasive bladder cancer, which means the cancer has not grown into the muscle layer of the bladder.^[1][2]

These studies compare a photodynamic diagnosis approach during transurethral resection with standard white-light surgery.^[1][2] The main question is whether this approach helps doctors remove more disease and reduce the need for repeat surgery.^[1][2]

Who is being studied

The target population in both trials is people with non-muscle invasive bladder cancer (NMIBC).^[1][2] One trial lists the condition as “Not muscular invasive bladder cancer,” and the other uses the term NMIBC.^[1][2]

These studies are designed for patients who are having bladder tumor surgery and may need a second look operation later.^[1][2] The second trial explains that it is trying to identify patients who could safely avoid an unnecessary repeat resection.^[2]

How the trials are designed

Both studies are interventional, which means the research team assigns a treatment strategy and then measures the results.^[1][2] Both are also Phase 3 studies, so they compare the research approach with standard care in larger patient groups.^[1][2]

In NCT06548438, the study compares PDD during TURB with white-light cystoscopy (WLC).^[1] The trial includes 300 participants and is focused on the completeness of the first tumor removal.^[1]

In 2023-507307-64-00, the study compares a primary PDD-guided TURBT strategy with the standard pathway that includes white-light resection and a repeat resection when needed.^[2] This trial includes 258 participants and looks at whether some patients can avoid a second operation.^[2]

Main endpoints

The main endpoint in NCT06548438 is the proportion of patients with residual tumor or a new diagnosis of carcinoma in situ at the time of repeat TURB.^[1] Residual tumor means cancer still found after the first surgery, and carcinoma in situ means an early flat cancer change in the bladder lining.^[1]

The main endpoint in 2023-507307-64-00 is the relative proportion of patients with early bladder cancer recurrence at the first follow-up cystoscopy.^[2] Early recurrence is defined differently in the two study arms because the treatment timelines are not the same.^[2]

Both trials are therefore measuring how well the surgery removes visible and hidden disease, not just whether the procedure can be done.^[1][2]

What the trials try to show

The first study aims to compare the completeness of TURB with PDD against TURB with white light.^[1] It asks whether the PDD-guided approach leaves fewer patients with remaining tumor or upstaging at repeat surgery.^[1]

The second study aims to provide strong evidence that a PDD-guided approach may be safe enough to reduce or avoid unnecessary repeat resections in selected NMIBC patients.^[2] The brief summary says the investigators want to show that their approach is not oncologically inferior to standard care, meaning it should not be worse for cancer control.^[2]

These studies are important because they focus on a practical question in bladder cancer care: whether better imaging during surgery can improve treatment and possibly reduce extra procedures.^[1][2]

Key patient terms

• TURBT is surgery through the urethra to remove a bladder tumor.^[2]

• Repeat resection means a second surgery after the first tumor removal to check for leftover disease.^[1][2]

• Follow-up cystoscopy is a later bladder check with a camera to look for cancer coming back.^[2]

• Standard of care means the usual treatment doctors already use in regular practice.^[2]

• Oncologically inferior means worse for cancer control, which the second trial aims to rule out.^[2]

Table of Contents

• What is Follitropin Alfa?
• How Does It Work?
• Conditions Treated
• Administration
• Effectiveness
• Side Effects
• Comparison with Other Treatments
• Ongoing Research

What is Follitropin Alfa?

Follitropin alfa is a medication used in fertility treatments. It is a type of hormone known as a recombinant human follicle-stimulating hormone (r-hFSH). This means it is a laboratory-made version of the natural hormone that stimulates egg production in women^[1]. Follitropin alfa is known by several brand names, including Gonal-F, Puregon, Primapur, and Gonapure^[2][3].

How Does It Work?

Follitropin alfa works by stimulating the ovaries to produce more than one egg at a time. In a natural menstrual cycle, usually only one egg matures and is released. However, for certain fertility treatments, it’s beneficial to have multiple mature eggs available^[4]. The medication mimics the action of the body’s natural follicle-stimulating hormone, encouraging the growth and development of ovarian follicles, which contain the eggs^[5].

Conditions Treated

Follitropin alfa is primarily used to treat infertility in women. It is prescribed for various conditions and procedures, including:

• Assisted Reproductive Technologies (ART): This includes treatments like in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI)^[6].
• Ovulation Induction: For women who do not ovulate regularly or at all^[7].
• Controlled Ovarian Stimulation: To produce multiple eggs for fertility treatments^[8].
• Female Infertility: Various causes of infertility in women^[3].

Administration

Follitropin alfa is typically administered as a subcutaneous injection, meaning it is injected just under the skin. The medication often comes in pre-filled pens or syringes for easy self-administration at home^[2]. The dosage and duration of treatment can vary depending on the individual patient and the specific fertility treatment plan. Generally, the starting dose is between 75-150 IU (International Units) per day, and treatment may last for 7-16 days^[6][2].

Effectiveness

The effectiveness of follitropin alfa is typically measured by several factors:

• Number of oocytes retrieved: This refers to the number of eggs collected after stimulation. A higher number of eggs generally increases the chances of successful fertilization and pregnancy^[2].
• Quality of oocytes: The medication aims to produce mature, high-quality eggs suitable for fertilization^[3].
• Pregnancy rates: This includes biochemical pregnancies (early positive pregnancy test) and clinical pregnancies (confirmed by ultrasound)^[2].
• Live birth rates: The ultimate measure of success in fertility treatments^[9].

Studies have shown that follitropin alfa is effective in stimulating ovarian follicle development and increasing the number of mature eggs available for fertility treatments^[6].

Side Effects

Like all medications, follitropin alfa can cause side effects. Common side effects may include:

• Injection site reactions (redness, pain, itching, swelling, bruising)^[8]
• Headache
• Abdominal pain or bloating
• Nausea
• Ovarian Hyperstimulation Syndrome (OHSS): A condition where the ovaries become swollen and painful. This is a serious but rare side effect that requires immediate medical attention^[3].

It’s important to discuss potential side effects with your healthcare provider before starting treatment.

Comparison with Other Treatments

Follitropin alfa is one of several gonadotropins used in fertility treatments. Other similar medications include:

• Corifollitropin alfa (Elonva): This is a long-acting FSH that requires less frequent injections^[4].
• Follitropin beta (Puregon): Another type of recombinant FSH^[10].
• Follitropin delta (Rekovelle): A newer recombinant FSH that is dosed based on the patient’s weight and AMH levels^[8].

Studies have been conducted to compare the efficacy and safety of these different treatments. Generally, they have been found to have similar effectiveness, with some differences in dosing schedules and individualization of treatment^[4][8].

Ongoing Research

Research on follitropin alfa and other fertility treatments is ongoing. Current areas of study include:

• Comparing different dosing protocols to optimize treatment outcomes^[9].
• Investigating the effects of different stimulation protocols on embryo development^[4].
• Studying the efficacy and safety of biosimilar versions of follitropin alfa^[6].
• Exploring combination treatments with other medications to improve outcomes^[7].

These ongoing studies aim to further improve the effectiveness and safety of fertility treatments using follitropin alfa and related medications.

Table of Contents

• What is Etoposide?
• How Etoposide Works
• Conditions Treated with Etoposide
• How Etoposide is Administered
• Etoposide in Combination Therapies
• Potential Side Effects
• Ongoing Research and Clinical Trials

What is Etoposide?

Etoposide is a chemotherapy drug used to treat various types of cancer. It’s also known by other names such as VP-16 or VP-16,213^[1]. Etoposide belongs to a class of drugs called topoisomerase inhibitors, which work by interfering with the cancer cells’ ability to divide and grow^[2].

How Etoposide Works

Etoposide targets a specific protein in cancer cells called topoisomerase II. This protein is essential for cancer cells to divide and multiply. By inhibiting topoisomerase II, etoposide prevents cancer cells from growing and spreading, ultimately leading to their death^[2]. Understanding how etoposide affects cancer cells helps researchers develop more effective treatment strategies and combinations with other drugs.

Conditions Treated with Etoposide

Etoposide is used to treat various types of cancer, including:

• Small Cell Lung Cancer (SCLC): This is an aggressive form of lung cancer for which etoposide is commonly used in combination with other drugs^[2][3].
• Non-Hodgkin’s Lymphoma: A type of blood cancer affecting the lymphatic system^[4].
• Brain and Central Nervous System Tumors: Including ependymomas, which are tumors that form in the brain or spinal cord^[1].
• Acute Leukemias: Cancers of the blood and bone marrow^[5].
• Testicular Cancer: Particularly in cases of seminoma, a type of testicular cancer^[6].

How Etoposide is Administered

Etoposide can be given in different ways, depending on the specific treatment plan and type of cancer:

• Intravenous (IV) Injection: Etoposide is often given through a vein over a period of time. For example, it may be administered daily for 3-5 days as part of a treatment cycle^[1][3].
• Oral Capsules: In some cases, etoposide can be taken by mouth in capsule form. This allows for more convenient at-home treatment in certain situations^[2][4].

The dosage and schedule of etoposide administration can vary based on factors such as the type of cancer, the patient’s overall health, and whether it’s being used alone or in combination with other treatments.

Etoposide in Combination Therapies

Etoposide is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combinations include:

• Etoposide + Cisplatin: This combination is frequently used in treating small cell lung cancer and other solid tumors^[1][7].
• Etoposide + Carboplatin: Another combination used in lung cancer treatment^[6].
• Etoposide + Mitoxantrone: Used in treating certain types of leukemia^[8].
• Etoposide + Cyclophosphamide + Cisplatin: A combination used in treating lymphomas and other cancers^[9].

These combinations are designed to target cancer cells in multiple ways, potentially increasing the effectiveness of treatment while managing side effects.

Potential Side Effects

Like all chemotherapy drugs, etoposide can cause side effects. It’s important to discuss these with your healthcare provider. Common side effects may include:

• Lowered blood counts (white blood cells, red blood cells, and platelets), which can increase the risk of infection, anemia, and bleeding
• Nausea and vomiting
• Hair loss
• Fatigue
• Loss of appetite
• Mouth sores

Your healthcare team will monitor you closely for these and other potential side effects and may adjust your treatment plan as needed^[7].

Ongoing Research and Clinical Trials

Researchers continue to study etoposide to improve its effectiveness and explore new applications. Some areas of ongoing research include:

• Combination with newer drugs: Studies are looking at combining etoposide with newer targeted therapies or immunotherapies to enhance treatment outcomes^[7].
• Personalized medicine approaches: Research is exploring how genetic factors might influence a patient’s response to etoposide, potentially leading to more tailored treatment plans^[2].
• New formulations: Scientists are investigating different ways of delivering etoposide to improve its effectiveness or reduce side effects.
• Expanded use in other cancer types: Clinical trials are exploring the use of etoposide in treating additional types of cancer or at different stages of disease^[10].

These ongoing studies aim to improve treatment outcomes and quality of life for patients receiving etoposide-based therapies.

Table of Contents

• What is Decitabine?
• What Conditions Does Decitabine Treat?
• How Does Decitabine Work?
• How is Decitabine Administered?
• Dosage and Treatment Schedules
• Potential Side Effects
• Effectiveness of Decitabine
• Ongoing Research and Future Directions

What is Decitabine?

Decitabine, also known by the brand name Dacogen, is a medication used to treat certain blood disorders and cancers^[1][3]. It belongs to a class of drugs called hypomethylating agents, which work by affecting how genes are expressed in cells^[3].

What Conditions Does Decitabine Treat?

Decitabine is primarily used to treat the following conditions:

• Myelodysplastic Syndrome (MDS): A group of blood disorders where the bone marrow doesn’t produce enough healthy blood cells^[3][5]
• Chronic Myelomonocytic Leukemia (CMML): A type of blood cancer that affects certain white blood cells^[1][3]
• Acute Myeloid Leukemia (AML): A fast-growing cancer of the blood and bone marrow^[2][10]

In some cases, decitabine is being studied for use in other conditions, such as certain types of solid tumors like pancreatic cancer^[11].

How Does Decitabine Work?

Decitabine works by affecting the way genes are used in cells. Specifically, it blocks a process called DNA methylation, which can sometimes cause genes to be turned off when they shouldn’t be^[3]. By interfering with this process, decitabine can help:

• Reactivate genes that control normal cell growth and development
• Promote the production of healthy blood cells
• Slow down or stop the growth of cancer cells

How is Decitabine Administered?

Decitabine is typically given in one of two ways:

1. Intravenous (IV) infusion: The drug is given directly into a vein over a period of time, usually 1-3 hours^[1][3]
2. Oral tablet: A newer form of decitabine (combined with another drug called cedazuridine) can be taken by mouth^[10]

The method of administration depends on the specific condition being treated and the treatment plan determined by your doctor.

Dosage and Treatment Schedules

The dosage and schedule for decitabine can vary depending on the condition being treated and the individual patient. Some common treatment schedules include:

• 20 mg/m² given intravenously over 1 hour, once daily for 5 days, repeated every 4 weeks^[1]
• 15 mg/m² given intravenously over 3 hours, three times a day for 3 consecutive days, repeated every 6 weeks^[3]
• For the oral form (ASTX727), one tablet containing 35 mg decitabine and 100 mg cedazuridine, taken once daily for 5 days, repeated every 4 weeks^[10]

Your doctor will determine the best dosage and schedule for your specific situation.

Potential Side Effects

Like all medications, decitabine can cause side effects. Some of the most common side effects include:

• Fatigue
• Nausea and vomiting
• Decreased blood cell counts (which can lead to increased risk of infection, bleeding, or anemia)
• Fever
• Diarrhea
• Constipation

Your healthcare team will monitor you closely for side effects and can help manage them if they occur^[10].

Effectiveness of Decitabine

Clinical trials have shown that decitabine can be effective in treating MDS, CMML, and AML in some patients. Effectiveness is often measured by:

• Overall response rate: The percentage of patients whose disease improves with treatment^[10]
• Complete remission: When there are no detectable signs of the disease after treatment^[10]
• Improved blood cell counts: Increases in healthy red blood cells, white blood cells, or platelets^[5]
• Transfusion independence: When patients no longer need blood or platelet transfusions^[10]
• Overall survival: How long patients live after starting treatment^[10]

The effectiveness can vary depending on the specific condition and individual patient factors.

Ongoing Research and Future Directions

Researchers continue to study decitabine to find new ways to use it and improve its effectiveness. Some areas of ongoing research include:

• Combining decitabine with other drugs to enhance its effects^[2]
• Using decitabine in new types of cancers, such as pancreatic cancer^[11]
• Developing new ways to administer the drug, such as the oral form (ASTX727)^[10]
• Studying how decitabine affects specific genetic markers in cancer cells to predict which patients might benefit most from the treatment^[11]

These ongoing studies may lead to new and improved treatments for blood disorders and cancers in the future.

Table of Contents

• What is Dabrafenib?
• How Dabrafenib Works
• Conditions Treated with Dabrafenib
• Combination Therapy with Trametinib
• How Dabrafenib is Administered
• Clinical Trials and Research
• Potential Side Effects
• Patient Monitoring During Treatment

What is Dabrafenib?

Dabrafenib is a medication used in the treatment of certain types of cancer. It is also known by its brand name Tafinlar and is sometimes referred to by its research code GSK2118436^[1]. Dabrafenib belongs to a class of drugs called BRAF inhibitors, which target a specific genetic mutation found in some cancer cells^[2].

How Dabrafenib Works

Dabrafenib works by blocking a protein called BRAF, which plays a central role in the growth and survival of cancer cells with a specific genetic mutation called BRAF V600. By inhibiting this protein, Dabrafenib can help slow down or stop the growth of cancer cells^[3].

The BRAF mutation is like a faulty switch that keeps cancer cells growing uncontrollably. Dabrafenib acts like a targeted “off switch” for this faulty mechanism, potentially slowing or stopping cancer growth.

Conditions Treated with Dabrafenib

Dabrafenib is primarily used to treat the following conditions:

• Melanoma: A type of skin cancer, particularly when it has spread to other parts of the body (metastatic) or cannot be removed by surgery^[4].
• Non-small cell lung cancer: A type of lung cancer with the BRAF V600E mutation^[5].
• Anaplastic thyroid cancer: An aggressive form of thyroid cancer^[5].
• Other solid tumors: Dabrafenib is being studied for use in other types of cancers that have the BRAF V600 mutation^[5].

Combination Therapy with Trametinib

Dabrafenib is often used in combination with another drug called Trametinib (brand name Mekinist). This combination therapy has shown improved effectiveness in treating certain cancers compared to using Dabrafenib alone^[4].

The combination works by targeting two different parts of the same cellular pathway. While Dabrafenib blocks the BRAF protein, Trametinib inhibits another protein called MEK. This dual approach can lead to better cancer control and may help prevent or delay the development of drug resistance.

How Dabrafenib is Administered

Dabrafenib is typically taken orally in capsule form. The usual dose is 150 mg twice daily, approximately 12 hours apart^[6]. However, the exact dosage and schedule may vary depending on the specific condition being treated and the patient’s individual factors. It’s crucial to take Dabrafenib exactly as prescribed by your healthcare provider.

Clinical Trials and Research

Numerous clinical trials have been conducted to study the effectiveness and safety of Dabrafenib. These trials have investigated its use in various stages of melanoma, including:

• As an adjuvant treatment (after surgery) for high-risk melanoma to prevent recurrence^[6].
• In combination with Trametinib for advanced melanoma that has spread to the brain^[2].
• For other types of cancers with the BRAF V600 mutation, such as thyroid cancer^[3].

Ongoing research continues to explore new potential uses for Dabrafenib and ways to optimize its effectiveness.

Potential Side Effects

Like all medications, Dabrafenib can cause side effects. Some of the most common side effects include:

• Fever (pyrexia)
• Fatigue
• Skin changes (rash, dry skin)
• Headache
• Joint pain

More serious side effects can occur, although they are less common. These may include the development of new skin cancers, eye problems, or heart rhythm changes^[1]. It’s important to report any new or worsening symptoms to your healthcare provider promptly.

Patient Monitoring During Treatment

While on Dabrafenib treatment, patients typically undergo regular monitoring. This may include:

• Blood tests to check liver function and other health markers^[1].
• Heart monitoring with electrocardiograms (ECGs)^[2].
• Skin examinations to check for new skin cancers^[1].
• Eye exams to check for any vision changes^[1].
• Imaging scans to assess the cancer’s response to treatment^[6].

These monitoring procedures help ensure the treatment is working effectively and allow for early detection of any potential side effects.

Table of Contents

• What is Azacitidine?
• What Conditions Does Azacitidine Treat?
• How Does Azacitidine Work?
• How is Azacitidine Administered?
• Potential Side Effects
• Current Clinical Trials
• Combination Therapies

What is Azacitidine?

Azacitidine is a medication used in the treatment of various blood disorders. It’s known by several names, including:

• 5-Azacytidine
• 5-AZC
• Vidaza
• Ladakamycin
• Mylosar

This drug belongs to a class of medications called hypomethylating agents, which work by affecting how genes are expressed in cells^[1].

What Conditions Does Azacitidine Treat?

Azacitidine is primarily used to treat several blood disorders, including:

• Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells^[2].
• Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow^[3].
• Chronic Myelomonocytic Leukemia (CMML): A rare blood cancer that affects certain white blood cells^[1].

These conditions all involve problems with blood cell production or function, which Azacitidine aims to improve.

How Does Azacitidine Work?

Azacitidine works by influencing how genes are expressed in cells. Specifically, it:

• Blocks certain enzymes that affect DNA, potentially stopping the growth of cancer cells^[4].
• Helps “turn on” genes that may have been incorrectly turned off in cancer cells.
• May help restore normal blood cell production in the bone marrow.

By affecting gene expression, Azacitidine can potentially slow down or stop the growth of abnormal cells while allowing healthy cells to develop normally.

How is Azacitidine Administered?

Azacitidine can be given in several ways:

• Subcutaneous (SC) injection: Injected under the skin^[5].
• Intravenous (IV) infusion: Given directly into a vein^[6].
• Oral tablets: Taken by mouth (a newer formulation being studied)^[1].

The most common dosing schedule is 75 mg/m² (based on body surface area) given daily for 7 days, followed by 21 days of rest. This 28-day cycle is typically repeated for several months^[2].

Potential Side Effects

Like all medications, Azacitidine can cause side effects. Common ones may include:

• Fatigue
• Nausea and vomiting
• Diarrhea or constipation
• Decreased blood cell counts, which can lead to increased risk of infections, bruising, or bleeding
• Injection site reactions (if given subcutaneously)

It’s important to discuss potential side effects with your healthcare provider, as they can help manage these issues if they occur^[7].

Current Clinical Trials

Azacitidine is being studied in various clinical trials to:

• Improve its effectiveness when combined with other drugs^[3].
• Explore its use in different types of cancer^[4].
• Develop new formulations, such as oral tablets^[1].
• Compare it to other treatments or treatment combinations^[6].

These trials aim to find better ways to use Azacitidine and potentially expand its use to help more patients.

Combination Therapies

Researchers are exploring how Azacitidine works when combined with other medications. Some combinations being studied include:

• Azacitidine with Venetoclax for AML^[3].
• Azacitidine with Lenalidomide for high-risk MDS^[2].
• Azacitidine with Entinostat for lung cancer^[4].
• Azacitidine with Glasdegib for AML, MDS, and CMML^[7].

These combinations aim to improve treatment outcomes by targeting cancer cells in multiple ways simultaneously.

Table of contents

• Overview of Atorvastatin research
• Cardiovascular and brain trials
• Trials in other conditions
• Study design, phases, and participants
• Main endpoints used in the trials
• Trial status and what it means

Overview of Atorvastatin research

The trial data show that Atorvastatin is being studied in many different clinical settings, including prevention of heart and brain events, cancer care, migraine, and other diseases.^[1][2] These are research studies, not a drug guide, and they focus on whether Atorvastatin helps in specific patient groups.^[3]

Most trials are Phase 2 or Phase 3, which means researchers are testing whether the treatment works and how safe it is in larger groups.^[4] A smaller number of studies are Phase 1 or low-intervention studies, and one bioequivalence study compared two formulations in healthy volunteers.^[5]

Cardiovascular and brain trials

Several studies focus on people with cardiovascular disease or high risk of it, such as atherosclerosis, acute coronary syndrome, and high polygenic risk for coronary artery disease.^[2][6] These trials measure outcomes like major cardiovascular events, cardiovascular death, heart attack, stroke, and plaque progression in blood vessels.^[2][7]

One large Phase 3 study in people with high polygenic risk for coronary artery disease is testing whether preventive statin treatment can lower the chance of major cardiovascular events and death.^[6] Another Phase 3 study in people with atherosclerotic cardiovascular disease is measuring time to cardiovascular death, non-fatal heart attack, or non-fatal ischemic stroke.^[7]

Trials also include people with covert brain infarction, ischemic stroke, transient ischemic attack, and spontaneous lobar intracerebral hemorrhage.^[1][8] In these studies, researchers are looking at outcomes such as MACCE, MACE-free survival, recurrent hemorrhage, and major bleeding or other safety events.^[1][8]

Some studies compare continuing statins with stopping them after brain bleeding or stroke, while others test whether statin treatment helps older frail patients after ischemic stroke or transient ischemic attack.^[8][9] One trial in frail adults aged 70 and older also measures health-related quality of life with PROMIS-10.^[9]

Trials in other conditions

Atorvastatin is also being tested in non-cardiovascular conditions, showing that the trial program is broad.^[10] These include bile acid diarrhoea, COPD, migraine, Graves ophthalmopathy, arrhythmogenic cardiomyopathy, and some cancer settings.^[10]

In bile acid diarrhoea, one low-intervention study is measuring a bile acid synthesis marker called C4 to see whether Atorvastatin lowers bile acid production.^[11] In COPD, a Phase 3 trial is comparing Atorvastatin with placebo to see whether it reduces exacerbations, which are flare-ups of symptoms.^[12]

In migraine, Phase 2 studies are testing whether Atorvastatin can reduce the number of migraine days per 4 weeks in episodic and chronic migraine.^[13] In Graves ophthalmopathy, researchers are studying whether Atorvastatin can prevent active eye disease after a new diagnosis of Graves’ disease, using the Clinical Activity Score as the main measure.^[14]

In cancer trials, Atorvastatin is being studied as part of treatment strategies for breast cancer, prostate cancer, non-small cell lung cancer, triple negative breast cancer, and metastatic cancers.^[15] These trials measure outcomes such as overall survival, invasive disease-free survival, progression, immune cell changes, and ctDNA changes, which are blood-based signs of tumor activity.^[15]

Study design, phases, and participants

Most trials are interventional, meaning the research team assigns a treatment or placebo and then compares results between groups.^[4] Some studies are blinded, which means patients or researchers may not know which treatment was given, helping reduce bias, or unfair influence on the results.^[11][16]

The enrolled populations are very different from one study to another.^[3] Some trials include healthy volunteers, while others focus on older frail adults, patients after stroke, people with atherosclerosis, people with cancer, or people with chronic inflammatory disease.^[3][9][15]

Enrollment ranges from very small studies with 8, 14, 20, or 36 participants to very large trials with more than 17,000 participants.^[5][7] This wide range shows that some studies are early or focused on special questions, while others are designed to give stronger answers in large patient groups.^[4]

Main endpoints used in the trials

The main endpoint is the primary result the trial is trying to measure.^[17] For Atorvastatin studies, common endpoints include major cardiovascular events, stroke, death, plaque volume, LDL-C change, quality of life, and disease progression.^[1][7][9]

Some trials use imaging endpoints, such as atherosclerotic plaque volume in the aorta or coronary arteries, or echocardiography, which is an ultrasound test of the heart.^[2][18] Other trials use lab endpoints, such as cholesterol and bile acid metabolism, sex steroid levels, inflammatory markers, or C4.^[11][19]

Several studies measure patient-centered outcomes, such as health-related quality of life, daily functioning, and treatment adherence.^[9][16] These outcomes help show how treatment affects daily life, not only test results.

Trial status and what it means

The trial list includes studies with different status labels: Authorised, Completed, and Withdrawn.^[1][5] Authorised means the study is approved to run, completed means the study has finished, and withdrawn means the study was stopped before completion.^[5]

Some trial titles include product names or drug combinations, but the main research question is still about Atorvastatin as part of a study strategy.^[20] Across the trial list, the same medicine is being tested for many different goals, from prevention to treatment support to mechanistic research.^[3]